Aptevo Therapeutics (APVO) Expected to Announce Earnings on Monday

Aptevo Therapeutics (NASDAQ:APVO) is anticipated to issue its results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($6.02) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($6.41) EPS for the quarter, hitting the consensus estimate of ($6.41). On average, analysts expect Aptevo Therapeutics to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Aptevo Therapeutics Stock Down 4.6%

NASDAQ APVO traded down $0.19 during trading hours on Monday, hitting $3.92. 3,073 shares of the company were exchanged, compared to its average volume of 100,354. The stock has a 50-day moving average price of $4.59 and a 200 day moving average price of $5.44. Aptevo Therapeutics has a 52 week low of $3.68 and a 52 week high of $50.40. The stock has a market cap of $4.88 million, a PE ratio of -0.02 and a beta of 1.66.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aptevo Therapeutics currently has an average rating of “Hold”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.